Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20086450 | 0.84 | TYR (0.49) | L3MBTL1TYRLMNANPC1RAB9A | |
| SCHEMBL20819381 | 0.81 | TYR (0.47) | L3MBTL1TYRLMNAPOLBNPC1 | |
| SCHEMBL758061 | 0.81 | L3MBTL1 (1.00) | L3MBTL1TYRLMNAPOLBNPC1 | |
| SCHEMBL27890416 | 0.80 | L3MBTL1 (0.62) | L3MBTL1POLBNPC1RAB9AMEN1 | |
| SCHEMBL2744060 | 0.79 | L3MBTL1 (0.62) | L3MBTL1TYRPOLBNPC1RAB9A | |
| SCHEMBL9570949 | 0.79 | MAPT (0.60) | L3MBTL1TYRLMNAPOLBNPC1 | |
| SCHEMBL27944093 | 0.79 | TYR (0.57) | L3MBTL1TYRLMNANPC1RAB9A | |
| SCHEMBL4875411 | 0.79 | CYP1A2 (0.71) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| Bromide SCHEMBL2241396 | 0.78 | L3MBTL1 (0.60) | L3MBTL1TYRPOLBNPC1RAB9A | |
| SCHEMBL1808047 | 0.78 | L3MBTL1 (0.70) | L3MBTL1LMNAPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331538-B1 | CRYSTALLINE FORMS OF A 2-THIAZOLYL- 4-QUINOLINYL-OXY DERIVATIVE, A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2687526-A1 | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8362035-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-8362035-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-20120270775-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270775-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-8232293-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232293-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20120142929-A1 | PROCESS FOR PREPARING SULFONYL QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142929-A1 | PROCESS FOR PREPARING SULFONYL QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010107965-A1 | PROCESS FOR PREPARING SULFONYL QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | WO | disclosed |
| CN-1794988-B | Composition for treating vascular hyperpermeable disease | SUCAMPO AG | 2010-07-28 | — | — | CN | disclosed |
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010033444-A1 | CRYSTALLINE FORMS OF A 2-THIAZOLYL- 4-QUINOLINYL-OXY DERIVATIVE, A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | WO | disclosed |
| CN-1794988-A | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | L3MBTL1 4444/4885TYR 4008/4885LMNA 3920/4885 |
| US-20120270775-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | L3MBTL1 4444/4885TYR 4008/4885LMNA 3920/4885 |
| US-20120142929-A1 | PROCESS FOR PREPARING SULFONYL QUINOLINES | GYS2, CYP3A7, GBA1 | L3MBTL1 4850/4885TYR 1100/4885LMNA 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.